Literature DB >> 9855167

Elevated tear interleukin-6 levels in patients with Sjögren syndrome.

M Tishler1, I Yaron, O Geyer, I Shirazi, E Naftaliev, M Yaron.   

Abstract

OBJECTIVE: The purpose of the study was to investigate interleukin-6 (IL-6) levels in the tear fluid and sera of patients with Sjögren syndrome (SS). PARTICIPANTS: Twelve patients with primary SS and 12 normal control subjects participated. INTERVENTION: Tear fluid and sera were obtained from the study and the control groups. Evaluation of tear fluid and sera IL-6 levels was done by using a quantitative enzyme-linked immunosorbent assay kit. All assays were carried out blindly with respect to diagnosis. MAIN OUTCOME MEASURES: Tear fluid IL-6 levels were measured.
RESULTS: The mean concentration (+/- standard error) of IL-6 in the tears of patients with SS was elevated significantly compared to that of normal control subjects (88.6+/-16.2 vs. 42.1+/-10.6 pg/ml; P < 0.05). No significant differences were noted in the serum IL-6 levels between the two groups. A significant correlation (r = 0.742, P = 0.006) was found between tear fluid IL-6 levels and the focus score of lip biopsy specimens in patients with SS.
CONCLUSION: Tear fluid IL-6 levels may serve as an important marker for tear gland involvement in SS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855167     DOI: 10.1016/S0161-6420(98)91236-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  32 in total

Review 1.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

Review 2.  Mechanisms involved in injury and repair of the murine lacrimal gland: role of programmed cell death and mesenchymal stem cells.

Authors:  Driss Zoukhri
Journal:  Ocul Surf       Date:  2010-04       Impact factor: 5.033

Review 3.  Effect of inflammation on lacrimal gland function.

Authors:  Driss Zoukhri
Journal:  Exp Eye Res       Date:  2005-11-23       Impact factor: 3.467

4.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

Authors:  Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2013-08-14       Impact factor: 3.467

Review 5.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

6.  Corneal epithelial proliferation and thickness in a mouse model of dry eye.

Authors:  Claudia Fabiani; Stefano Barabino; Saadia Rashid; M Reza Dana
Journal:  Exp Eye Res       Date:  2009-03-17       Impact factor: 3.467

7.  Cis-urocanic acid suppresses UV-B-induced interleukin-6 and -8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro.

Authors:  J Viiri; H M Jauhonen; A Kauppinen; T Ryhänen; T Paimela; J Hyttinen; I Sorri; J K Laihia; L Leino; K Kaarniranta
Journal:  Mol Vis       Date:  2009-09-08       Impact factor: 2.367

8.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.

Authors:  Amalia Enríquez-de-Salamanca; Evangelina Castellanos; Michael E Stern; Itziar Fernández; Ester Carreño; Carmen García-Vázquez; Jose M Herreras; Margarita Calonge
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

Review 9.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

10.  Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease.

Authors:  Shimin Li; Karina Nikulina; Jason DeVoss; Ava J Wu; Erich C Strauss; Mark S Anderson; Nancy A McNamara
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.